Skip to Content

MYLAN 2250 MYLAN 2250 (Mycophenolate mofetil 250 mg)

Pill imprint MYLAN 2250 MYLAN 2250 has been identified as Mycophenolate mofetil 250 mg.

Mycophenolate mofetil is used in the treatment of nephrotic syndrome; systemic lupus erythematosus; dermatomyositis; organ transplant, rejection prophylaxis; rheumatoid arthritis (and more), and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Mycophenolate mofetil 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil 250 mg MYLAN 2250 MYLAN 2250
Mycophenolate mofetil
MYLAN 2250 MYLAN 2250
250 mg
Tan / Purple
19.00 mm
Prescription only
Drug Class:
Selective immunosuppressants
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
Inactive Ingredients:
silicon dioxide
croscarmellose sodium
magnesium stearate
microcrystalline cellulose
corn starch
sodium lauryl sulfate
ferrosoferric oxide
FD&C Blue No. 2
ferric oxide red
titanium dioxide
ferric oxide yellow
propylene glycol
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
51079-0721 UDL Laboratories Inc

Note: Inactive ingredients may vary.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.